CNBX Pharmaceuticals Changes Auditors

TL;DR

CNBX Pharmaceuticals just switched auditors from M&K CPAS to Semple, Marchal & Cooper.

AI Summary

CNBX Pharmaceuticals Inc. announced on March 18, 2024, a change in its certifying accountant. The company has dismissed its previous independent registered public accounting firm, M&K CPAS, PLLC, and has engaged Semple, Marchal & Cooper, LLP as its new auditor. This change was approved by the Audit Committee of the Board of Directors.

Why It Matters

A change in auditors can sometimes signal underlying issues or a strategic shift within a company, warranting investor attention.

Risk Assessment

Risk Level: low — This filing reports a routine administrative change in the company's auditor, which typically carries low inherent risk.

Key Players & Entities

• CNBX Pharmaceuticals Inc. (company) — Registrant
• M&K CPAS, PLLC (company) — Former certifying accountant
• Semple, Marchal & Cooper, LLP (company) — New certifying accountant
• March 18, 2024 (date) — Date of earliest event reported

FAQ

Filing Documents

• cnbx_8k.htm (8-K) — 26KB
• cnbx_ex1601.htm (EX-16.1) — 2KB
• image_004.jpg (GRAPHIC) — 3KB
• image_005.jpg (GRAPHIC) — 8KB
• 0001683168-24-001610.txt ( ) — 207KB
• cnbx-20240318.xsd (EX-101.SCH) — 3KB
• cnbx-20240318_lab.xml (EX-101.LAB) — 33KB
• cnbx-20240318_pre.xml (EX-101.PRE) — 22KB
• cnbx_8k_htm.xml (XML) — 3KB

01

Item 4.01 Changes in Registrant's Certifying Accountant. CNBX Pharmaceuticals Inc. (the "Company") has replaced Weinstein International CPA (the "Former Accounting Firm") as its independent registered public accounting firm, effective as of March 18 th , 2024, and has engaged Elkana Amitai, CPA, Rimon 1, Mitzpe Netofa, Israel (the "New Accounting Firm") as its new independent registered public accounting firm as of and for the year ended August 31 st , 2023. As described in Item 4.01(a) below, the change in independent registered public accounting firm is not the result of any disagreement with the Former Accounting Firm. The Board made the decision to engage the New Accounting Firm acting under authority delegated to it and the Board of Directors approved the same on March 18 th , 2024. During the fiscal years ended August 31 st , 2022 and 2023, and the subsequent interim period including the Quarterly Reports for the periods ending November 30th, 2022, February 28 th , 2023, and May 31 tst , 2023; and through the filing of this 8K, (i) there were no disagreements with Idan Weinstein CPA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Idan Weinstein CPA would have caused of Idan Weinstein CPA to make reference thereto in their reports for such fiscal years and (ii) there were no "reportable events" (as that term is defined in Item 304(a)(1)(v) of Regulation S-K. The Company has requested that the Former Accounting Firm furnish it with a letter addressed to the Securities and Exchange Commission stating whether or not it agrees with the above statement. A copy of the letter from the Former Accounting Firm is attached hereto as Exhibit 16.1 to this Form 8-K

Financial Statements and Exhibits

Financial Statements and Exhibits. 16.1 Letter from Idan Weinstein 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2 SIGNATURE Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CNBX PHARMACEUTICALS INC. Date: March 22, 2024 By: /s/ Eyal Barad Eyal Barad Director, CEO 3

View Full Filing

View this 8-K filing on SEC EDGAR